ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,013.13
      -1.71%
      US Tech 100
      21,038.40
      -2.10%
      Dow Jones
      43,428.02
      -1.69%
      Brent Oil
      73.935
      0.00%
      Bitcoin
      96,246.75
      0.11%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Recursion Pharmaceuticals Inc (RXRX)

      7. Recursion Pharmaceuticals Inc (RXRX) News

      Recursion Pharmaceuticals Inc

      Recursion Pharmaceuticals Inc (RXRX)

      NASDAQ
      9.28
      -1.07
      (-10.34%)
      Closed February 21 4:00PM
      Delayed by 15 minutes
      9.27
      -0.01
      (-0.11%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      RXRX News

      Official News Only

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 20 2025
      RXRX (-10.34%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 20 2025
      RXRX (-10.34%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 07 2025
      RXRX (-10.34%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      February 06 2025
      RXRX (-10.34%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 05 2025
      RXRX (-10.34%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 05 2025
      RXRX (-10.34%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      February 05 2025
      RXRX (-10.34%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      January 30 2025
      RXRX (-10.34%)

      RXRX Discussion

      View Posts
      bwrbad bwrbad 1 day ago
      Big volume -- could be green EOD
      👍️0
      bwrbad bwrbad 3 days ago
      once cross 36 - it is open sky.
      everyday dips are the advantage point
      buying the $200 -$300 /sh stock of 2025 at $11 -$36
      👍️0
      bwrbad bwrbad 3 days ago
      could move $3 -$5 today
      👍️0
      bwrbad bwrbad 6 days ago
      https://x.com/RecursionChris/status/1747265218437349847
      👍️0
      TucsonPhil TucsonPhil 1 week ago
      I'd wager that undisclosed information is at play, but that wouldn't be legal, so couldn't possibly be the case.
      👍️0
      3antar 3antar 1 week ago
      So why do you think it keeps going higher! 
      👍️0
      bwrbad bwrbad 1 week ago
      blindfold buy at 20 - 30 then the jump 100 - 200
      👍️0
      bwrbad bwrbad 1 week ago
      RXRX
      👍️0
      TucsonPhil TucsonPhil 1 week ago
      They announce a mixed shelf (dilution), and the price spikes?
      👍️0
      bwrbad bwrbad 1 week ago
      RXRX just started little little sprinting step before planting the pole and jump over that record high pole vault bar
      👍 1
      bwrbad bwrbad 1 week ago
      invest - - soon --- before out of reach.
      👍️0
      bwrbad bwrbad 1 week ago
      this is a stock will gain 200-300% in a single day-- but today - no - it will go back to +3c or -3c in 1h
      👍️0
      TucsonPhil TucsonPhil 2 weeks ago
      This level of result, will make this company fly:

      https://www.globenewswire.com/news-release/2025/02/05/3021646/0/en/Recursion-Presents-Phase-2-Data-for-REC-994-in-CCM-in-Late-Breaking-Oral-Presentation-at-the-International-Stroke-Conference.html
      👍️ 1
      bwrbad bwrbad 2 weeks ago
      generative AI in making medical miracle
      👍️0
      bwrbad bwrbad 2 weeks ago
      REC-994 MRI-based brainstem lesion volume reduction : place a $M maker brick now
      👍️0
      bwrbad bwrbad 2 weeks ago
      70 institution 30 public--that's how RXRX drug working now
      👍️0
      bwrbad bwrbad 3 weeks ago
      YouTube influencer position - write or call cGibson@recursion.com
      👍️0
      TucsonPhil TucsonPhil 3 weeks ago
      Exactly, when we see the lending fees start to rise, then I will buy more. Brokers always make money, even when investors lose.
      👍️0
      bwrbad bwrbad 3 weeks ago
      they all do etard fidal TDA, but that gives the opportunity to buy low. This RxRx defines the future of MED world in AI stage- just buying little little within affordability. definitively it will grow like MSTF GOOG AAPL NVDA AMZN.., All drug lords pfizer, j&j eli, merck roche AZ BMS are lining up behind, just give few months to a year for first $100
      👍️0
      TucsonPhil TucsonPhil 3 weeks ago
      Fidelity is loaning shares to shorts.
      👍️0
      bwrbad bwrbad 3 weeks ago
      next piece of clinical update will take it above 20 and after that it is in different league.
      👍️0
      bwrbad bwrbad 4 weeks ago
      Sure looks like early days of ISRG ILMN,
      👍️0
      TucsonPhil TucsonPhil 4 weeks ago
      Nvidia invested $50M in this company. ARK is a holder. This will be huge, once their first find gets FDA approval, and proof of concept is secured.
      👍️ 1
      bwrbad bwrbad 4 weeks ago
      interesting no posters in this
      future $200 - $300 stock, and that future not far - see the quality of clinical data, target diseases, and the time it took to reach there - not standard 20 ys but 3y to ph3 and a large advancing failure resistant AI powered pipeline
      👍️0
      bwrbad bwrbad 4 weeks ago
      change of heart -going up.
      👍️0
      bwrbad bwrbad 4 weeks ago
      rxrx WORLD
      👍️0
      bwrbad bwrbad 1 month ago
      promised to accumulate 10k shares before Q end and hold for years. predict this issue never go BK, do RS, and one day go beyond 200+ like established big cap security issues.
      👍️0
      bwrbad bwrbad 1 month ago
      bandwagon
      👍️0
      bwrbad bwrbad 1 month ago
      believe in miracle ----- come to RXRX------
      👍️0
      TucsonPhil TucsonPhil 1 month ago
      Looks like Lilly is late to the party.

      https://www.statnews.com/2025/01/10/eli-lilly-andreessen-horowitz-500-million-venture-fund-ai-focus/
      👍️0
      bwrbad bwrbad 1 month ago
      cursion-re-cursion in flame after FDA REC 3565 blessings
      👍️0
      bwrbad bwrbad 2 months ago
      Gibson🤢🥵🥶😷Gibson
      👍️0
      bwrbad bwrbad 2 months ago
      baby nvda
      👍 1
      bwrbad bwrbad 2 months ago
      balding haircut at RXRX
      👍️0
      Monksdream Monksdream 2 months ago
      RXRX, under $7
      👍️0
      bwrbad bwrbad 2 months ago
      out for now, let CEO work his magic if he has one under his sleeve
      👍️0
      bwrbad bwrbad 2 months ago
      is something wrong with RxRx, it looked promising based on what said to public. but something not right. ground shaken up. - like trouble.
      what wrong with the CEO. if this continues that is bad sign for future of the company and the CEO.
      👍️0
      bwrbad bwrbad 2 months ago
      RXRX
      👍️0
      bwrbad bwrbad 2 months ago
      RxRx partnership: GOOG NVDA MSFT Roche/Genentech Bayer Bristol Myers Squibb Sanofi Merck ......
      👍 1
      bwrbad bwrbad 2 months ago
      RxRx M&A: Valence –Cyclica - Exscientia
      Valence – a leader in generative AI and deep learning models
      Cyclica - a deep learning engine that predicts the polypharmacology of small molecules in drug discovery.
      Exscientia - AI-driven precision medicine
      RXRX - Regenerative AI - TechBio powerhouse
      undergoing post merger reorganization, some job cuts
      enough cash to fund through 2027
      Ark Q3 2024 Stake: $215.9 million
      Hedge Fund Investors Q3 2024:: 16
      more than ten drugs in trials.
      👍️0
      bwrbad bwrbad 2 months ago
      market up big and RxRx ignored,
      if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.
      👍️0
      TucsonPhil TucsonPhil 2 months ago
      RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

      If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.
      👍️ 1
      bwrbad bwrbad 2 months ago
      Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
      Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
      Shares Outstanding 6 388.94M; Float 8 252.42M
      clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

      % Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%
      👍️ 1
      JJ8 JJ8 2 months ago
      Rxrx share price Long Tail Up since 06 Dec 2024.
      👍️0
      paperman paperman 2 months ago
      Phase 1 news expected tonight at conference.
      👍️0
      paperman paperman 2 months ago
      Phase 1 news expected tonight at conference.
      👍️0
      bwrbad bwrbad 2 months ago
      this is one magnificent AI drug discovery platform - be household name like google tesla Microsoft ...
      👍️0
      JJ8 JJ8 3 months ago
      Bought it yesterday at $6.60

      Today it's up about 22%.

      Same story with 2 other stocks and they all go up today more than 20%!

      Whoa! IN CREDIBLE!
      👍️0
      TucsonPhil TucsonPhil 3 months ago
      Agreed, but there will be wild swings, until they get their footing with clinical trials proving the concept works. Trade it until then, and keep one foot in the door for surprise announcements.
      👍️0
      bwrbad bwrbad 3 months ago
      RxRx going to be top player in future pharma drug discovery
      👍️0

      Your Recent History

      NASDAQ
      RXRX
      Recursion Pharmaceuticals
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads